Pemetrexed Monotherapy for Performance Status 2 Patients in Treatment of Non-Small and Non-Squamous Cell Lung Cancer Patients Without EGFR Mutation.

Trial Profile

Pemetrexed Monotherapy for Performance Status 2 Patients in Treatment of Non-Small and Non-Squamous Cell Lung Cancer Patients Without EGFR Mutation.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Sep 2015

At a glance

  • Drugs Pemetrexed (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Aug 2012 Planned End Date changed from 1 Feb 2012 to 31 Aug 2014 as reported by University Hospital Medical Information Network - Japan record.
    • 21 Oct 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top